Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP™) as epigenetic treatment for myelodysplastic syndrome (MDS)

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Annals of Hematology

• Publication date

  2017-08-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00277-017-3103-xPMID 28831600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.

  2017cited by this paper
• The early clinical development of Ebola virus treatments

  2017cited by this paper
• Incidence, etiology and timing of infections following azacitidine therapy for myelodysplastic syndromes

  2017cited by this paper
• Efficacy of hydralazine and valproate in cutaneous T-cell lymphoma, a phase II study

  2017cited by this paper
• Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

  2017cited by this paper
• The Incidence and Health Care Resource Burden of the Myelodysplastic Syndromes in Patients in Whom First-Line Hypomethylating Agents Fail.

  2017cited by this paper
• Distinct roles for TET family proteins in regulating human erythropoiesis.

  2017cited by this paper
• Genetics and Epigenetics of Myelodysplastic Syndromes and Response to Drug Therapy: New Insights

  2016cited by this paper
• The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

  2016cited by this paper
• Azacitidine with or without Entinostat for the treatment of therapy‐related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study

  2016cited by this paper
• The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes

  2015cited by this paper
• Myelodysplastic syndromes: 2015 Update on diagnosis, risk‐stratification and management

  2015cited by this paper
• Results of phase 2 randomized study of low‐dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia

  2015cited by this paper
• DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML

  2014cited by this paper
• Induction of Tet3-dependent Epigenetic Remodeling by Low-dose Hydralazine Attenuates Progression of Chronic Kidney Disease

  2014cited by this paper
• Hydralazine–valproate: a repositioned drug combination for the epigenetic therapy of cancer

  2014cited by this paper
• Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2014cited by this paper
• A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers

  2014cited by this paper
• Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

  2013cited by this paper
• Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes

  2013cited by this paper
• Myelodysplastic syndromes: state of the art pathology, diagnosis and management.

  2013cited by this paper
• DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells

  2012cited by this paper
• Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid

  2011cited by this paper
• Acetylator status and N-acetyltransferase 2 gene polymorphisms; phenotype–genotype correlation with the sulfamethazine test

  2011cited by this paper
• Hypomethylating agents and other novel strategies in myelodysplastic syndromes.

  2011cited by this paper
• Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.

  2010cited by this paper
• Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial

  2010cited by this paper
• DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.

  2010cited by this paper
• Mutation in TET2 in myeloid cancers.

  2009cited by this paper
• Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

  2009cited by this paper
• 5 ' Azacitidine in Combination with Valproic Acid Induces Complete Remissions in Patients with Advanced Acute Myeloid Leukaemia but Does Not Eradicate Clonal Leukaemic Stem/Progenitor Cells.

  2008cited by this paper
• A novel interaction between the proto‐oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a

  2008cited by this paper
• Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.

  2007cited by this paper
• Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes.

  2007cited by this paper
• Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.

  2006cited by this paper
• Decitabine improves patient outcomes in myelodysplastic syndromes

  2006cited by this paper
• Valproate Induces Replication-independent Active DNA Demethylation*

  2003cited by this paper
• Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

  2002cited by this paper
• Allelic discrimination using fluorogenic probes and the 5' nuclease assay

  1999cited by this paper
• Allelic discrimination using fluorogenic probes and the 5' nuclease assay.

  1999cited by this paper
• International scoring system for evaluating prognosis in myelodysplastic syndromes.

  1997cited by this paper
• Hematopoietic regulation mediated by interactions among the neurokinins and cytokines.

  1997cited by this paper

• The inhibitory and transcriptional effects of the epigenetic repurposed drugs hydralazine and valproate in lymphoma cells.

  2024cites this paper
• Antimicrobial activity of hydralazine against methicillin-resistant and methicillin-susceptible Staphylococcus aureus.

  2024cites this paper
• Patenting trends by Mexican pharmaceutical companies.

  2024cites this paper
• Targeting epigenetic regulation for cancer therapy using small molecule inhibitors.

  2023cites this paper
• Efficacy and safety of compassionate use for rare diseases: a scoping review from 1991 to 2022

  2023cites this paper
• Synergistic effect of hydralazine associated with triazoles on Candida spp. in planktonic cells.

  2023cites this paper
• Hydralazine Associated With Reduced Therapeutic Phlebotomy Frequency in a Nationwide Cohort Study: Real-World Effectiveness for Drug Repurposing

  2022cites this paper
• Epigenetics-Associated Risk Reduction of Hematologic Neoplasms in a Nationwide Cohort Study: The Chemopreventive and Therapeutic Efficacy of Hydralazine

  2022influential citation
• Molecular Imaging in neuroendocrine neoplasias Review in Quarterly Medical Review.

  2022cites this paper
• Effect of epigenetic treatment on SST2 expression in neuroendocrine tumour patients

  2022cites this paper
• Efficacy and Safety of Valproic Acid in Myelodysplastic Syndrome and Acute Myeloid Leukemia; a Narrative Review

  2022cites this paper
• Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges

  2020cites this paper
• Implications of genome plasticity for drug development

  2020cites this paper
• Repurposing old drugs to fight multidrug resistant cancers.

  2020cites this paper
• Hydralazine Sensitizes to the Antifibrotic Effect of 5-Aza-2′-deoxycytidine in Hepatic Stellate Cells

  2020cites this paper
• HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia

  2020cites this paper
• Megakaryocyte lineage development is controlled by modulation of protein acetylation

  2018cites this paper
• Down syndrome-like acute megakaryoblastic leukemia in a patient with Cornelia de Lange syndrome

  2017cites this paper